THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Michael Gold to Paclitaxel

This is a "connection" page, showing publications Michael Gold has written about Paclitaxel.
Connection Strength

0.357
  1. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann Oncol. 2024 Aug; 35(8):728-738.
    View in: PubMed
    Score: 0.216
  2. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007 May; 105(2):299-303.
    View in: PubMed
    Score: 0.065
  3. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021 06 10; 39(17):1842-1855.
    View in: PubMed
    Score: 0.044
  4. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol. 2008 Feb; 108(2):342-7.
    View in: PubMed
    Score: 0.017
  5. Carcinosarcoma of the ovary-a case series. Gynecol Oncol. 2006 Jan; 100(1):128-32.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES